Testicular germ cell tumors (GCTs) are highly curable with cisplatin-based chemotherapy. Achieving cure while minimizing acute and late toxicities requires precise dosing, individualized regimen selection, and proactive survivorship planning—especially for adolescent and young adult (AYA) patients and those with renal impairment. This review synthesizes recent guidance and foundational standards from the US, EU, and global practice to provide a clinically actionable overview.

1) Dosing principles and regimen selection

• Standard first-line BEP (bleomycin–etoposide–cisplatin) remains the cornerstone for metastatic GCTs and is used as adjuvant therapy in selected early-stage patients. Typical day-by-day BEP dosing is cisplatin 20 mg/m² and etoposide 100 mg/m² on days 1–5, with bleomycin 30 units given weekly (often days 1, 8, 15) every 21 days; EP (etoposide–cisplatin) for 4 cycles is an established alternative when bleomycin is contraindicated 22.
• For clinical stage I nonseminomatous GCT (NSGCT) with high-risk features (e.g., lymphovascular invasion), contemporary European guidance supports adjuvant single-cycle BEP (BEP × 1) to reduce recurrence while minimizing long-term toxicity 20.
• For stage I seminoma, single-agent carboplatin (AUC 7) is accepted as non-inferior to radiotherapy for relapse prevention and is widely used as adjuvant therapy 22.
• Cisplatin remains the preferred platinum in metastatic NSGCT; carboplatin substitution is reserved for patients unable to receive cisplatin (e.g., significant renal impairment, severe ototoxicity risk, or inability to tolerate hydration) because outcomes may be inferior if carboplatin replaces cisplatin in metastatic nonseminomatous disease 2122.

Practical variations:

• A compressed BEP schedule (bleomycin 30 IU on days 1, 3, 5 with cisplatin 20 mg/m² and etoposide 100 mg/m² on days 1–5; every 21 days) has real-world support for feasibility and safety (5-year OS 86% overall; low pulmonary event rate 1.46% without bleomycin-related deaths) and can improve convenience in some systems 8.
• Etoposide label dosing in combinations commonly uses 100 mg/m²/day for 5 days, repeated every 21 days after hematologic recovery; renal/hepatic impairment may necessitate adjustment with close monitoring 1.

Bleomycin cumulative dose and pulmonary risk:

• Product labels cap lifetime bleomycin dose at ≤400 units due to sharply increased pulmonary toxicity above this threshold; monitoring with weekly chest X-ray during treatment and monthly DLCO is advised, with discontinuation if DLCO falls to ~30–35% of baseline or if clinical/radiographic pneumonitis appears 567.
• Some guidance notes lower cumulative limits (≈270 units) and emphasizes that toxicity can occur at lower doses in susceptible patients; centers vary in cap and monitoring intensity 22.

2) Adolescent and young adult (AYA) patients

AYAs (typically 15–39 years) account for most GCTs and have unique needs:

• Guideline-concordant care is strongly linked to superior survival in AYAs with testicular primaries; treatment at specialized cancer centers increases adherence to standards and outcomes 9.
• Tolerability priorities include ototoxicity (cisplatin-related, often permanent), neuropathy, and psychosocial support. Baseline and serial audiometry are recommended, especially as cumulative cisplatin approaches ≥300 mg/m²; proactive neuropathy screening and counseling are important 2314.
• Coordination across pediatric and adult oncology improves adherence, fertility counseling, and survivorship transitions 2019.
• Regarding pharmacogenomics for ototoxicity, the retrieved materials report no established guideline consensus endorsing routine TPMT or ACYP2 testing for cisplatin ototoxicity prediction in AYA GCTs; risk assessment remains primarily clinical with audiometric monitoring 24.

3) Fertility preservation

• Cisplatin and carboplatin impair spermatogenesis; azoospermia is common during therapy, with recovery in many but not all men over 2–3 years. Sperm cryopreservation before chemotherapy is the standard of care and should be arranged urgently at diagnosis, ideally before treatment begins; 2–3 ejaculates are typically sought to maximize post-thaw viability 1134.
• Baseline semen quality is frequently depressed in testicular cancer even prior to treatment; azoospermia is present in a subset, warranting alternative collection methods when needed (e.g., electroejaculation, surgical sperm retrieval) 1211.
• Contraception recommendations vary by agent and product label; patients should follow drug-specific guidance regarding contraception duration during and after treatment; detailed counseling on assisted reproductive options post-treatment is essential 34.
• Survivorship programs should revisit fertility goals and offer post-treatment fertility assessment, recognizing that only a minority ultimately use banked sperm but many derive psychosocial benefit from preservation 1618.

4) Baseline renal impairment: thresholds, hydration, substitution

Cisplatin

• Label cautions include withholding cisplatin for significant renal dysfunction; some labels list contraindication at serum creatinine >2.3 mg/dL and require normalization before repeat dosing. Baseline and pre-cycle monitoring of creatinine, BUN, creatinine clearance, and electrolytes (Mg, Na, K, Ca) are mandatory 23.
• Kidney-function–driven frameworks (e.g., ADDIKD, KDIGO) recommend using eGFR (CKD-EPI) for most patients, with measured GFR preferred where feasible for cisplatin and carboplatin dosing, and stepwise adjustments by CKD category with multidisciplinary input in moderate–severe CKD 21.
• Practical hydration has evolved toward short-duration (2–6 hours), lower-volume (2–4 L) isotonic saline regimens with routine magnesium supplementation to reduce hypomagnesemia and nephrotoxicity. Evidence for routine mannitol is mixed; some reviews support its inclusion, while other contemporary protocols de-emphasize or remove routine mannitol, reserving it for high-dose cisplatin or select patients per local policy 2421.
• Avoid concurrent nephrotoxins (e.g., aminoglycosides, NSAIDs) and supplement electrolytes proactively, especially magnesium 2324.

Carboplatin

• Dose using Calvert formula: Dose (mg) = target AUC × (GFR + 25); common AUC targets are 5–7 depending on setting. Labels also provide initial mg/m² guidance by creatinine clearance strata (e.g., CrCl 41–59 mL/min: 250 mg/m²; 16–40 mL/min: 200 mg/m²) with caution below 15 mL/min 4.
• Carboplatin requires no aggressive hydration and is preferred when significant renal impairment limits cisplatin use 422.

Bleomycin

• Substantial renal impairment warrants bleomycin dose reduction across creatinine clearance bands, due to increased exposure and pulmonary risk (e.g., reductions to 70% at CrCl 40–50 mL/min, down to ~40% at CrCl 5–10 mL/min) 567.

5) Survivorship and late effects

Long-term risks are substantial and require structured follow-up:

• Cardiovascular disease: Cisplatin-based therapy increases early arterial thromboembolic event (ATE) risk (≈1.4% within 1 year) and contributes to long-term cardiovascular morbidity. A simple score (age ≥35, smoking, LDH ≥250 IU/L) stratifies long-term ATE risk up to 25 years; ATEs are associated with excess mortality 15. Aggressive risk-factor management and counseling are recommended 1427.
• Secondary malignancy: Elevated risk after chemotherapy and historical radiotherapy necessitates tailored screening and survivorship counseling 1427.
• Ototoxicity: High-frequency, dose-dependent hearing loss can be permanent; baseline and serial audiometry are recommended during and after cisplatin, particularly with cumulative doses >300 mg/m² 2314.
• Renal dysfunction: Chronic kidney disease can emerge years after cisplatin. Annual creatinine/eGFR and urinalysis monitoring is recommended 1427.
• Peripheral neuropathy: Cisplatin-related neuropathy can be persistent; routine symptom screening and supportive care are required 14.
• Pulmonary toxicity: Bleomycin-related pneumonitis/fibrosis can be insidious and progressive; periodic PFTs and imaging are recommended based on cumulative dose and symptoms 56714.

Follow-up schedules

• NCCN-based surveillance after remission incorporates frequent tumor markers in years 1–2, with imaging tapered from 1–2 times per year to annual by years 3–5; beyond 5 years, a survivorship-focused plan is appropriate 2223.
• COG long-term follow-up for pediatric/AYA survivors includes audiometry for higher cumulative cisplatin exposure, renal monitoring, endocrine assessment, and psychosocial screening; routine low-risk echocardiograms are no longer recommended in the latest update 19.

6) Comparative safety considerations and high-risk triggers

Acute toxicities

• Febrile neutropenia, nausea/vomiting, electrolyte wasting (notably hypomagnesemia), nephrotoxicity, and hypersensitivity reactions (cisplatin anaphylactoid) are key acute issues; pre-cycle labs and supportive care readiness are essential 234.
• Bleomycin idiosyncratic reactions (~1% overall) should prompt close observation after first doses; lymphoma protocols often use test dosing, though this is less relevant in GCT 56.

Late effects

• Cardiometabolic risk, ototoxicity, renal dysfunction, neuropathy, and secondary cancers drive long-term morbidity; monitoring intensity should scale with cumulative exposure (cisplatin, bleomycin) and baseline risk factors (age, smoking, renal function) 142715.

High-risk features warranting regimen modification or intensified monitoring

• Baseline eGFR <60 mL/min/1.73 m² (consider carboplatin substitution, measured GFR, and multidisciplinary dosing) 21.
• Cumulative bleomycin approaching 300–400 units, new respiratory symptoms, or DLCO decline (>15–20% from baseline in many centers) should trigger reassessment and potential bleomycin cessation; anesthesia teams must limit FiO₂ to ~25% perioperatively in bleomycin-exposed patients 567.
• Rapid audiometric decline or tinnitus during cisplatin requires dose discussion, otology referral, and counseling; routine audiometry is recommended 23.
• Refractory grade 3–4 cytopenias or recurrent febrile neutropenia may necessitate dose delays/reductions and growth factor support per institutional thresholds 22.

Summary Table: Special Populations, Key Risks, and Practical Recommendations

Practical takeaways

• Use cisplatin-based BEP whenever feasible for metastatic disease; reserve carboplatin for clear contraindications to cisplatin. For adjuvant settings, BEP ×1 (NSGCT) and single-dose carboplatin AUC 7 (seminoma) are contemporary options that balance efficacy and long-term toxicity 2022.
• Prioritize kidney-sparing strategies for cisplatin: short hydration with isotonic saline plus magnesium is evidence-supported; mannitol use varies by institution and patient risk; avoid nephrotoxins 242123.
• Track and manage cumulative doses: intensify pulmonary monitoring as bleomycin approaches 300–400 units and stop promptly for toxicity; intensify audiometric surveillance as cumulative cisplatin increases 56723.
• In AYAs, guarantee pre-treatment fertility counseling and sperm banking, treat at specialized centers, and plan for long-term survivorship risks and transitions 11919.
• Embed survivorship early: address cardiovascular risk, renal monitoring, hearing and neuropathy assessments, and tailored secondary malignancy screening in all long-term survivors 142722.

Where evidence is evolving or heterogeneous (e.g., precise bleomycin discontinuation thresholds by DLCO, routine mannitol use, and pharmacogenomic screening for cisplatin ototoxicity in AYAs), local protocols and multidisciplinary judgment should guide individualized decisions, with careful documentation and patient-centered counseling 24567.